LEADER 02256oam  2200601   450 
001 9910712086203321
005 20190326141651.0
035   $a(CKB)5470000002489236
035   $a(OCoLC)557033305$z(OCoLC)649750190
035   $a(EXLCZ)995470000002489236
100   $a20100315d1981      ua             0
101 0 $aeng
135   $aurbn||||||ada
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aNarcotic antagonists $enaltrexone pharmacochemistry and sustained-release preparations /$feditors: Robert E. Willette, Gene Barnett
210  1$aRockville, Maryland :$cDepartment of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse, Division of Research,$d1981.
215   $a1 online resource (viii, 1 unnumbered page, 276 pages) $cillustrations
225 1 $aDHHS publication ;$vno. (ADM) 81-102
225 1 $aNIDA research monograph ;$v28
320   $aIncludes bibliographical references.
517   $aNarcotic antagonists 
606   $aNaltrexone$xPhysiological effect$zUnited States
606   $aNarcotic antagonists$xPhysiological effect$zUnited States
606   $aDrugs$xControlled release$zUnited States
606   $aHeroin abuse$xTreatment$zUnited States
606   $aDrugs$xControlled release$2fast
606   $aHeroin abuse$xTreatment$2fast
606   $aNarcotic antagonists$xPhysiological effect$2fast
615  0$aNaltrexone$xPhysiological effect
615  0$aNarcotic antagonists$xPhysiological effect
615  0$aDrugs$xControlled release
615  0$aHeroin abuse$xTreatment
615  7$aDrugs$xControlled release.
615  7$aHeroin abuse$xTreatment.
615  7$aNarcotic antagonists$xPhysiological effect.
702   $aWillette$b Robert E.
702   $aBarnett$b Gene
712 02$aNational Institute on Drug Abuse.$bDivision of Research,
801  0$bOCLCE
801  1$bOCLCE
801  2$bOCLCQ
801  2$bOCLCO
801  2$bOCLCQ
801  2$bOCLCF
801  2$bOCLCO
801  2$bOCLCA
801  2$bGPO
906   $aBOOK
912   $a9910712086203321
996   $aNarcotic antagonists$93464305
997   $aUNINA